SSTR2 and cancer: Although the clinical relevance of such overexpression is unclear, the difference in the expression in cancerous and normal tissue creates the preconditions for the use of SSTR2 ligands as an effective targeting moiety to provide a cancer-specific delivery of therapeutics and the possible limitation of adverse side effects upon healthy tissues.